Literature DB >> 7103444

Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations.

D E Zaske, R J Cipolle, J C Rotschafer, L D Solem, N R Mosier, R G Strate.   

Abstract

The pharmacokinetics and dosage requirements of gentamicin were studied in 1,640 patients receiving treatment for gram-negative infections. A wide interpatient variation in the kinetic parameters of the drug occurred in all patients and in patients who had normal serum creatinine or normal creatinine clearance. The half-life ranged from 0.4 to 32.7 h in 331 patients who had normal creatinine clearance. The factors related to the elimination rate constant were creatinine clearance, age, distribution volume, weight, gender, and hematocrit. The daily dose necessary to obtain therapeutic serum concentrations ranged from 0.5 to 25.8 mg/kg in patients with normal serum creatinine and from 0.7 to 25.8 mg/kg in patients with normal creatinine clearance. In 13 patients (0.9%), a significant change in base-line serum creatinine (greater than or equal to 0.5 mg/dl) occurred during or after treatment, which may have been gentamicin-associated toxicity. Overt cochlear or vestibular toxicity did not occur in these patients. The method of individualizing dosage regimens provided a clinically useful means of rapidly attaining therapeutic peak and trough serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7103444      PMCID: PMC181905          DOI: 10.1128/AAC.21.3.407

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Gentamicin: toxicity in perspective.

Authors:  W L Hewitt
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

2.  The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

Authors:  D Kaye; M E Levison; E D Labovitz
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

3.  Gentamicin in newborn infants. Comparison of intramuscular and intravenous administration.

Authors:  J W Paisley; A L Smith; D H Smith
Journal:  Am J Dis Child       Date:  1973-10

4.  Correlation of serum creatinine concentration and gentamicin half-life.

Authors:  R E Cutler; A M Gyselynck; W P Fleet; A W Forrey
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

5.  Pharmacokinetics of gentamicin: distribution and plasma and renal clearance.

Authors:  A M Gyselynck; A Forrey; R Cutler
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  Gentamicin therapy in renal failure: a nomogram for dosage.

Authors:  R A Chan; E J Benner; P D Hoeprich
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

7.  Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.

Authors:  G G Jackson; L J Riff
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Gentamicin dosages for renal insufficiency. Adjustments based on endogenous creatinine clearance and serum creatinine concentration.

Authors:  M C McHenry; T L Gavan; R W Gifford; N A Geurkink; R A Van Ommen; M A Town; J G Wagner
Journal:  Ann Intern Med       Date:  1971-02       Impact factor: 25.391

9.  Predictability of blood levels of gentamicin in man.

Authors:  M Barza; R B Brown; D Shen; M Gibaldi; L Weinstein
Journal:  J Infect Dis       Date:  1975-08       Impact factor: 5.226

10.  Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis.

Authors:  P Noone; T M Parsons; J R Pattison; R C Slack; D Garfield-Davies; K Hughes
Journal:  Br Med J       Date:  1974-03-16
View more
  36 in total

1.  Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation.

Authors:  C Triginer; I Izquierdo; R Fernández; J Torrent; S Benito; A Net; F Jane
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 3.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

4.  Bioelectrical impedance modelling of gentamicin pharmacokinetic parameters.

Authors:  B J Zarowitz; A M Pilla; E L Peterson
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 5.  Aminoglycoside therapy. Current use and future prospects.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

Review 6.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 8.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

9.  Increase of amikacin half-life during therapy in patients with renal insufficiency.

Authors:  J Blaser; S Rüttimann; H Bhend; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

10.  Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.

Authors:  F Konrad; R Wagner; B Neumeister; H Rommel; M Georgieff
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.